Thursday, September 21, 2023

Gene Therapy For Sickle Cell Disease

Here is a paper from several years ago, abstract:

Sickle cell disease results from a homozygous missense mutation in the β-globin gene that causes polymerization of hemoglobin S. Gene therapy for patients with this disorder is complicated by the complex cellular abnormalities and challenges in achieving effective, persistent inhibition of polymerization of hemoglobin S. We describe our first patient treated with lentiviral vector-mediated addition of an antisickling β-globin gene into autologous hematopoietic stem cells. Adverse events were consistent with busulfan conditioning. Fifteen months after treatment, the level of therapeutic antisickling β-globin remained high (approximately 50% of β-like-globin chains) without recurrence of sickle crises and with correction of the biologic hallmarks of the disease. (Funded by Bluebird Bio and others; HGB-205 ClinicalTrials.gov number, NCT02151526 .).

So, fifteen months of continued therapeutic benefit was observed.  That's very good and stable for that time period. We'll need to look into, and follow up on, continuing developments in this field; but in general, gene therapy opens up exciting avenues of novel therapeutics to treat a variety of inherited and sporadic disorders.

No comments:

Post a Comment